AA
CGON icon

AlphaCentric Advisors’s CG Oncology CGON Stock Holding History

AlphaCentric Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$37.7K – 222
2024
Q3 		$37.7K Hold
1,000
– – 0.03% 222
2024
Q2 		$31.6K Hold
1,000
– – 0.02% 213
2024
Q1 		$43.9K Buy
+1,000
New +$40.8K 0.03% 218

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AlphaCentric Advisors's CGON Position: Q4 2024 in Review

AlphaCentric Advisors sold out of CG Oncology (CGON) in Q4 2024, closing a stake of 1,000 shares — an estimated $37.7K sold.

AlphaCentric Advisors first reported a position in CGON in Q1 2024 and held it in 3 quarters. The position peaked at $43.9K in Q1 2024. 140 funds tracked by Wall St. Rank hold CGON as of Q4 2024.

  • AlphaCentric Advisors reported no remaining CG Oncology position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 1,000 CG Oncology shares in Q4 2024, an estimated $37.7K.
  • AlphaCentric Advisors first reported a position in CG Oncology in Q1 2024 and held it in 3 quarters.
  • AlphaCentric Advisors's CG Oncology position peaked at $43.9K in Q1 2024.
  • 140 funds tracked by Wall St. Rank held CG Oncology as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.